Media Articles Related to Rozerem (Ramelteon)
Insomniacs May Be More Sensitive to Pain
Source: MedicineNet Chronic Pain Specialty [2015.05.13]
Title: Insomniacs May Be More Sensitive to Pain
Category: Health News
Created: 5/12/2015 12:00:00 AM
Last Editorial Review: 5/13/2015 12:00:00 AM
Study links insomnia to impaired work performance in night shift workers
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2015.04.30]
A new study of night shift workers suggests that overnight occupational and cognitive impairment is more strongly correlated to insomnia than it is to sleepiness.
Source: MedicineNet Creutzfeldt-Jakob Disease Specialty [2014.07.17]
Category: Diseases and Conditions
Created: 6/6/2005 12:00:00 AM
Last Editorial Review: 7/17/2014 12:00:00 AM
Shift work linked to sleep problems, poor metabolic health
Source: Diabetes News From Medical News Today [2015.05.18]
A new study finds people who work shifts are more likely to experience sleep problems such as insomnia, which may increase their risk of obesity and diabetes.
Impaired sleep linked to lower pain tolerance
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2015.05.04]
People with insomnia and other sleep problems have increased sensitivity to pain, reports a study published in PAIN®, the official publication of the International Association for the Study of...
Published Studies Related to Rozerem (Ramelteon)
Ramelteon in the treatment of chronic insomnia: systematic review and
in the treatment of chronic insomnia... CONCLUSION: The efficacy and safety of ramelteon are promising for the chronic
Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. [2011.10.01]
STUDY OBJECTIVES: To evaluate the next-morning residual effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects following bedtime dosing and a middle of the night awakening... CONCLUSIONS: Ramelteon (8 mg) and zopiclone (7.5 mg) significantly impaired driving performance, cognitive, memory, and psychomotor performance the morning following bedtime administration. In contrast to zopiclone, ramelteon produced no balance impairments. CLINICAL TRIAL IDENTIFIER: NCT00319215 (www.clinicaltrials.gov).
Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. [2011.10]
OBJECTIVE: Few interventions have been successful to prevent or reverse the medical complications associated with antipsychotic agents in the schizophrenia population. In particular, no single agent can correct multiple metabolic abnormalities such as insulin resistance, hyperlipidemia, inflammation, obesity, and fat distribution. We now report a randomized placebo-controlled pilot study to examine the effects of ramelteon on obesity and metabolic disturbances among subjects with schizophrenia... CONCLUSIONS: Although ramelteon decreased cholesterol, treatment may have to be longer than 8 weeks and with a higher dose for maximal effect of ramelteon for body fat and lipid changes. Future studies are needed for patients with schizophrenia with a larger sample size to fully understand ramelteon's effects on abdominal adiposity and lipids.
Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study. [2011.02]
This randomized, double-blind, placebo-controlled study assessed the efficacy and safety of ramelteon 4 and 8 mg in Japanese adults with chronic insomnia. A secondary objective was to evaluate efficacy and safety when doses were uptitrated from placebo, ramelteon 4 and 8 mg to 4, 8 and 16 mg, respectively...
Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. [2011.02]
OBJECTIVE: To assess patient-reported efficacy and safety of ramelteon in Japanese patients with chronic insomnia... CONCLUSIONS: In Japanese adults with chronic insomnia, ramelteon 8 mg significantly reduced patient-reported sleep latency, increased total sleep time and improved sleep quality after 1 week of treatment. Ramelteon was generally well tolerated with no rebound insomnia. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Clinical Trials Related to Rozerem (Ramelteon)
A Study to Evaluate the Ability of Ramelteon to Alleviate the Insomnia Symptoms Associated With Eastward Bound Jet Lag in Healthy Adult Volunteers [Completed]
This is a study to evaluate the ability of ramelteon to alleviate the insomnia symptoms of
eastbound jet lag in healthy adult volunteers. Subjects are screened in Hawaii, and then
travel to the Eastern Time Zone for randomization to receive either ramelteon or a placebo
during evaluation in a sleep laboratory.
A Study to Evaluate the Phase-Shifting Effects of Repeated Daily Dosing of TAK-375 in Healthy Subjects [Completed]
This was a Dose-Ranging Study to Evaluate TAK-375 at 1 mg, 2 mg, 4 mg, or 8 mg versus a
placebo taken once daily for five days.
Treatment of Subjects With Mild to Moderate Alzheimer's Disease and Sleep Treatment of Subjects Who Have Mild to Moderate Alzheimer's Disease and Sleep Disturbance With Rozerem™ [Completed]
The purpose of the study is to determine if subjects with mild to moderate Alzheimer's
Disease and sleep disturbance will benefit from treatment with Rozerem.
Effect of Rozerem on the Perception of GERD Symptoms in Patients With Chronic Insomnia. [Recruiting]
To determine if administration of Rozerem in comparison to a placebo reduces or eliminates
gastroesophageal reflux disease(GERD) symptoms in individuals with both GERD and chronic
A Safety and Efficacy Study of TAK-375 in Adults With Chronic Insomnia [Completed]
This was a study to evaluate the efficacy and safety of 8 mg TAK-375, 16 mg of TAK-375 or a
placebo taken once daily in adults with chronic insomina for 7 weeks.
Reports of Suspected Rozerem (Ramelteon) Side Effects
Hepatic Function Abnormal (5),
Liver Disorder (5),
Cardio-Respiratory Arrest (5),
Depressed Level of Consciousness (5),
Pneumonia (3), more >>